Bristol-myers Squibb Company · NYSE:BMY
Bristol-myers Squibb — Shareholder Meeting (April 2017)
15 slides from Bristol-myers Squibb's shareholder meeting presentation, Apr 17, 2017
Slide 1: Specialty BioPharma Company Key Therapeutic Areas
Specialty BioPharma Company K ey Th erapeu tic A reas Bristol-Myers Squibb combines the agility of a biotech company with the resources and stability of a large pharmaceutical company Oncology Delivered 12 new products in past 6 years 19 major market approvals in 2016 – Immunoscience – Our research
Slide 2: 2016 Highlights
2016 Highlights We have achieved significant growth across key product portfolios, building on the strategic foundation established by our transformation to a specialty biopharmaceutical company $1,603 3500 $4, 000 $1, 800 $2, 500 $1, 200 $1, 800 Successfully transitioned to a specialty biopharmaceu
Slide 3: Immuno-Oncology and Pipeline Update
Immuno-Oncology and Pipeline Update Unprecedented Achievements: Opdivo: Unrivaled Speed of Approvals Global Approvals for Opdivo 200 > 10 11 Approved Indications 8 New England Journal of Medicine Publications 11 6 FDA Approvals in Opdivo 11 2 4 inYears 2 Breakthrough Therapy Designations 7 0 Opdivo
Slide 4: Board Leadership Transition
Board Leadership Transition Effective upon completion of the 2017 Annual Meeting of Shareholders on May 2, 2017, Lamberto Andreotti will retire as Chairman and a member of the Board. The Board has elected Dr. Giovanni Caforio to become the next Chairman of the Board. Secretary Togo D. West, Jr. will
Slide 5: Board Refreshment and Leadership Update
Board Refreshment and Leadership Update New Independent Directors: NOT FOR PRODUCT PROMOTIONAL USE 6 Theodore R. Samuels Former President of the Capital Guardian Trust Company • Extensive business and operational experience, particularly with respect to economics and investment decision making • Ser
Slide 6: Board Well Positioned to Support Company Strategy
Board Well Positioned to Support Company Strategy Comprehensive Board Expertise Harvard Business School 8 6 7 7 11 10 2 7 10 • Committees: Audit, CMDC (c) Range of Tenure >10 years (2 Directors) 5-10 years (3 Directors) = New Since 2013 Audit: Audit Committee CDCG: Committee on Directors & Corporate
Slide 7: Committed to Sound Corporate Governance
Committed to Sound Corporate Governance Board Accountability and Shareholder Rights The Board continues to place Proactive shareholder engagement Proxy access shareholder right a high priority on engagement with our shareholders Annual election of Directors Ability to call special meetings (25%) Maj
Slide 8: Executive Compensation Supporting our Strategy
Executive Compensation Supporting our Strategy Continued Commitment to our Compensation Philosophy and Structure 2016 Target Total CEO Compensation Com pet it iv e P rogram P ay 1 Base Salary 10% Attracts, retains, and incentivizes talented executives capable of leading our business in our highly co
Slide 9: 2016 Executive Compensation
2016 Executive Compensation Changes became effective in 2016 that further enhance the structural alignment between our incentive program and our strategy and directly reflect shareholder feedback Lengthened the performance period in our Performance Share Unit (PSU) program from one year to three yea
Slide 10: We Value Your Support at Our 2017 Annual Meeting
We Value Your Support at Our 2017 Annual Meeting NOT FOR PRODUCT PROMOTIONAL USE 11 Shareholder Proposal The request to reduce our special meeting ownership threshold from 25% to 15% is unnecessary given: – Our history of responsiveness to shareholders – Our adoption of proxy access, in addition to
Slide 11: 2012 Stock Award and Incentive Plan Proposals
2012 Stock Award and Incentive Plan Proposals NOT FOR PRODUCT PROMOTIONAL USE 12 Accordingly, our Board recommends a vote FOR both proposals relating to the 2012 Stock Award and Incentive Plan Approval of an Amendment to the Company’s 2012 Stock Award and Incentive Plan Sole purpose of the proposed
Slide 12: Forward-Looking and Non-GAAP Information
Forward-Looking and Non-GAAP Information This presentation contains statements about the Company’s future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995.Actual results may differ mat
Slide 13: Appendix
Appendix NOT FOR PRODUCT PROMOTIONAL USE 14
Slide 14: 2016-2017 Compensation Plan Structure
2016-2017 Compensation Plan Structure Factor against pre-defined and late-stage pipeline and in Human, Proof of Confidence, the performance of high value assets and the integration of NOT FOR PRODUCT PROMOTIONAL USE 15 Market Share Units (40%) Rewards creation of incremental shareholder value Provid
Slide 15: 2016-2017 Compensation Plan Structure
2016-2017 Compensation Plan Structure + Allows us to attract and retain talent in a highly competitive labor market ae + Set based on pay levels of comparable postions within peer aroup, as well as qualifications, experience and role characteristics STN) «ert increases based on individual performanc
Bristol-Myers Squibb — Shareholder Meeting (April 2017) on 6ix